Form 4: Collegium Pharmaceutical Director Acquires Shares as Compensation

Michael Thomas Heffernan, a director at Collegium Pharmaceutical, acquired 4,820 shares of common stock as compensation for his service as interim CEO.

Summary

• Michael Thomas Heffernan, a director of Collegium Pharmaceutical, acquired 4,820 shares of common stock on February 10, 2025.
• The acquisition was a grant of fully-vested restricted stock units (RSUs) as compensation for his service as interim Chief Executive Officer in 2024.
• Each RSU represents a contingent right to receive one share of Collegium Pharmaceutical's common stock.
• Following the transaction, Heffernan beneficially owns 50,328 shares of Collegium Pharmaceutical.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to compensation. The director's acquisition of shares could be seen as a slightly positive signal, but it's primarily a procedural matter.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals confidence from a company director.

Key Dates